You're right that we have no partnership financing details. Can't say the claims ENZC is paying Samsung are true, nor false, from the info we have today.
It doesn't particularly matter either, imo, since having Samsung be the CDMO is about as ideal a partnership for successfully producing these mAbs as we could wish for. ENZC needs the mAbs for trials which is part of the path to future revenue, so it's great to see them taking this step with Samsung, whoever's paying for it.